Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by PoorOpinionon Jun 08, 2018 5:18pm

146 Views

Post# 28148279

RE:RE:RE:Is it just me?

Great detective work. I'm assuming they already have a contract to deal with this relationship between ucalgary and antibe but typically work done by a university employee on university time that has commercial application is the property of the university as well as the inventors and commercial partners. The original paper has a "supported by" section which doesnt suggest Antibe paid for the work to be done which is one way to get around ownership issues, the work was funded by gov/charity grants. Work supported by charitable grants has another set of complex rules when it comes to commercialization

https://www.antibethera.com/wordpress/wp-content/uploads/2018/05/Motta-et-al-Inflamm-Bow-Dis-May-2018.pdf

I'm sure antibe could commercialize it eventually but its not the news that adds value atm. (Just) another example of why this team are excellent world-class scientists and possibly why the potential of lead drug should be taken seriously.

Jefferam1 wrote: From the research paper:
" ATB-428 and ATB-429 are compounds consisting of mesalamine covalently linked to an H2 S-donor: 4-hydroxythiobenzamide (TBZ) in the case of ATB-428, and (5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione, ADT-OH) in the case of ATB-429. These drugs were provided by Antibe Holdings Inc. (Calgary, Canada)."

Doesn't specifically say they hold the rights or the patents but kinda seems like they might.

Now I'm no chemest but patent expert... but from what I gather, Antibe has 2 h2s compounds, TBZ and ADT-OH
What ATB-428 and 429 is mesalamine linked to each of these compounds...
Looking at mesalimine definition... Says its 5-Aminosalicylic acid;

Now looking at the patents, canadian patent 2609224
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2609224/summary.html?query=antibe&start=1&num=50&type=basic_search

This is for DERIVATIVES OF 4-OR 5-AMINOSALICYLIC ACID

This patent is held by Antibe

In their abstract...
"The present invention provides new derivatives of 4-or 5-aminosalicylic acid,
and a pharmaceutical composition containing these derivatives of 4-or 5-
aminosalicylic acid as active ingredients, useful for the treatment of
intestinal diseases such as inflammatory bowel disease (IBD) and irritable
bowel syndrome (IBS) and for the prevention/treatment of colon cancer. More
particularly, these derivatives comprise a hydrogen sulfide releasing moiety
linked via an azo, an ester, an anhydride, a thioester or an amide linkage to
a molecule of 4-or 5-aminosalicylic acid. Furthermore, the present invention
provides a process for preparing these compounds and their use for treating
IBD and IBS and the prevention/treatment of colon cancer."

To me it kinda sounds like Antibe DOES hold the patent for ATB-428 and ATB-429

Can anyone validate this?
Seems like I might have gone about this the hard way, there must be an easier way to make this link.